Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$6.75 USD
-0.07 (-1.03%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $6.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.75 USD
-0.07 (-1.03%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $6.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit
by Zacks Equity Research
Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
by Zacks Equity Research
J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.
AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker
by Zacks Equity Research
AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
by Zacks Equity Research
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Are Medical Stocks Lagging Align Technology (ALGN) This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.
AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
by Zacks Equity Research
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
Here's Why You Should Invest in Alpine (ALPN) Stock Now
by Zacks Equity Research
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs
by Zacks Equity Research
Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.
Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 42.9% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 60% and 14.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
KalVista (KALV) Surges 15% on Update From Angioedema Study
by Zacks Equity Research
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
by Zacks Equity Research
Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.
Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 25% and 24.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.